세계의 응고 분석기 시장 예측(-2032년) : 제품별, 검사 종류별, 모달리티별, 기술별, 최종사용자별, 지역별 분석

According to Stratistics MRC, the Global Coagulation Analyzers Market is accounted for $5.13 billion in 2025 and is expected to reach $8.35 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Coagulation analyzers are automated diagnostic devices that evaluate the efficiency and timing of blood clot formation. They perform tests that identify abnormalities in clotting factors and assist in diagnosing issues like thrombosis, hemophilia, and liver-related disorders. Through automated assays such as PT, aPTT, and D-dimer, these analyzers provide reliable data for managing anticoagulant therapy, enabling healthcare professionals to make informed and rapid treatment decisions.

According to the Perth Blood Institute, as of July 2025, the prevalence of hemophilia in the male population worldwide was 1 in 6,000-10,000 in 2024, with hemophilia A affecting approximately 1 in 5,000 males and hemophilia B affecting approximately 1 in 30,000 males.

Market Dynamics:

Driver:

Increase in anticoagulant therapy use

As more patients undergo long-term treatment, the need for precise monitoring of coagulation parameters has intensified. Coagulation analyzers play a critical role in ensuring safe dosage and effective therapy outcomes. Hospitals and diagnostic centers are increasingly adopting advanced analyzers to support personalized treatment regimens. The growing elderly population, which is more prone to thrombotic conditions, further accelerates market expansion. Consequently, the surge in anticoagulant therapy use is a primary driver of growth in the coagulation analyzers market.

Restraint:

Limited awareness and infrastructure in developing regions

Many healthcare facilities lack adequate infrastructure to support advanced diagnostic equipment. High costs and insufficient reimbursement policies discourage investment in modern analyzers. Training gaps among medical professionals also hinder effective utilization of available technologies. Rural and underserved areas often rely on basic diagnostic methods, reducing market penetration. As a result, limited awareness and infrastructure continue to restrain growth in emerging economies.

Opportunity:

Increasing adoption of point-of-care (POC) testing

Portable analyzers allow clinicians to make immediate treatment decisions, improving patient outcomes. Rising demand for decentralized healthcare is driving adoption in homecare and emergency settings. Technological innovations are enhancing accuracy and usability of POC devices. Governments and private providers are investing in POC solutions to expand access in underserved regions. This growing trend represents a significant opportunity for manufacturers to broaden their market reach.

Threat:

Threat of substitute products

Some healthcare providers rely on manual testing or basic kits due to lower costs. Emerging technologies in molecular diagnostics and imaging may reduce dependence on traditional analyzers. Established substitutes often benefit from familiarity and lower training requirements. Price-sensitive markets may prefer these alternatives despite lower accuracy. Consequently, the threat of substitute products remains a notable risk for sustained market growth.

Covid-19 Impact:

The COVID-19 pandemic disrupted supply chains and delayed routine diagnostic procedures, affecting analyzer demand. However, the crisis highlighted the importance of coagulation testing in managing severe cases. Hospitals adopted rapid testing solutions to monitor clotting complications in COVID-19 patients. Remote diagnostics and decentralized testing gained traction during lockdowns. Post-pandemic strategies now emphasize resilience, digital integration, and wider accessibility of coagulation analyzers.

The prothrombin time (PT) segment is expected to be the largest during the forecast period

The prothrombin time (PT) segment is expected to account for the largest market share during the forecast period, due to its critical role in monitoring anticoagulant therapy. PT testing is widely used to assess clotting function in patients on warfarin and similar drugs. Its clinical relevance across cardiovascular and hematological conditions ensures consistent demand. Hospitals and diagnostic centers prioritize PT testing for routine monitoring and emergency care. The simplicity and reliability of PT assays make them a preferred choice globally.

The electrochemical technology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the electrochemical technology segment is predicted to witness the highest growth rate, due to its precision and efficiency. These analyzers offer rapid detection of clotting parameters with minimal sample volumes. Advances in sensor design and microfluidics are enhancing performance and reliability. Portable electrochemical devices are gaining popularity in point-of-care settings. Their cost-effectiveness and scalability make them attractive for both developed and emerging markets.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by advanced healthcare infrastructure and high awareness. The region benefits from strong adoption of anticoagulant therapies and routine coagulation monitoring. Favorable reimbursement policies support widespread use of advanced analyzers. Leading manufacturers are headquartered in the U.S., ensuring easy access to innovations. Continuous investment in R&D strengthens technological leadership in the region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by expanding healthcare infrastructure and rising patient volumes. Countries such as China and India are investing heavily in diagnostic modernization. Growing awareness of coagulation disorders is driving demand for advanced testing solutions. Government initiatives and public-private partnerships are fostering accessibility and affordability. The region's large population base and increasing prevalence of cardiovascular diseases amplify growth potential.

Key players in the market

Some of the key players in Coagulation Analyzers Market include Siemens H, Bio-Rad La, Sysmex Co, ERBA Man, Roche Dia, Diagnosti, Abbott Lab, Trinity Bio, Thermo Fi, Helena La, Instrumen, Nihon Koh, Beckman C, Mindray Me, and Horiba M.

Key Developments:

In November 2025, Siemens and Samsung C&T Corporation, Engineering & Construction Group have entered a strategic and long-term partnership. Grounded in mutual trust and complementary capabilities, the agreement aims to combine Samsung C&T's global engineering, procurement, and construction (EPC) expertise with Siemens' advanced technologies in automation, digitalization, electrification, and integrated infrastructure intelligence.

In July 2025, Bio-Rad Laboratories, Inc. announced the launch of four new Droplet Digital(TM) PCR (ddPCR(TM)) platforms. The newly introduced instruments include Bio-Rad's QX Continuum(TM) ddPCR system along with the QX700(TM) series of ddPCR platforms acquired as part of the company's recently completed acquisition of digital PCR developer Stilla Technologies.

Products Covered:

• Systems/Analyzers
• Consumables

Test Types Covered:

• Prothrombin Time (PT)
• Activated Partial Thromboplastin Time (APTT)
• Fibrinogen Testing
• D-Dimer Testing
• Anti-Thrombin III Testing
• Other Specialized Coagulation Tests

Modalities Covered:

• Central Laboratory Platforms
• Point-of-Care Platforms

Technologies Covered:

• Optical Technology
• Mechanical Technology
• Electrochemical Technology
• Other Technologies

End Users Covered:

• Hospitals
• Clinical Laboratories
• Diagnostic Centers
• Research Institutes
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Coagulation Analyzers Market, By Product

• 5.1 Introduction
• 5.2 Systems/Analyzers
  • 5.2.1 Automated Systems
  • 5.2.2 Semi-automated Systems
  • 5.2.3 Manual Systems
  • 5.2.4 Point-of-Care Testing Analyzers
• 5.3 Consumables
  • 5.3.1 Reagents
  • 5.3.2 Assays
  • 5.3.3 Standards
  • 5.3.4 Controls
  • 5.3.5 Calibrations

6 Global Coagulation Analyzers Market, By Test Type

• 6.1 Introduction
• 6.2 Prothrombin Time (PT)
• 6.3 Activated Partial Thromboplastin Time (APTT)
• 6.4 Fibrinogen Testing
• 6.5 D-Dimer Testing
• 6.6 Anti-Thrombin III Testing
• 6.7 Other Specialized Coagulation Tests

7 Global Coagulation Analyzers Market, By Modality

• 7.1 Introduction
• 7.2 Central Laboratory Platforms
• 7.3 Point-of-Care Platforms

8 Global Coagulation Analyzers Market, By Technology

• 8.1 Introduction
• 8.2 Optical Technology
• 8.3 Mechanical Technology
• 8.4 Electrochemical Technology
• 8.5 Other Technologies

9 Global Coagulation Analyzers Market, By End User

• 9.1 Introduction
• 9.2 Hospitals
• 9.3 Clinical Laboratories
• 9.4 Diagnostic Centers
• 9.5 Research Institutes
• 9.6 Other End Users

10 Global Coagulation Analyzers Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Siemens Healthineers
• 12.2 Bio-Rad Laboratories
• 12.3 Sysmex Corporation
• 12.4 ERBA Mannheim
• 12.5 Roche Diagnostics
• 12.6 Diagnostica Stago
• 12.7 Abbott Laboratories
• 12.8 Trinity Biotech
• 12.9 Thermo Fisher Scientific
• 12.10 Helena Laboratories
• 12.11 Instrumentation Laboratory
• 12.12 Nihon Kohden Corporation
• 12.13 Beckman Coulter
• 12.14 Mindray Medical International
• 12.15 Horiba Medical